The Latest Cardiac and Vascular News
Firibastat efficacy non-significant versus placebo The REFRESH study and the development of firibastat in cardiology have been stopped Cash of 11 million euros allotted to the development of new innovative treatments, after discontinuation of the REFRESH study PARIS, Oct. 28, […]
PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain to treat resistant/difficult to treat hypertension and heart-failure, […]
PARIS, Oct. 05, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain to treat resistant/difficult to treat hypertension and heart-failure, […]
PARIS, June 27, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat hypertension and heart failure, today announces the appointment of new […]
PARIS, May 09, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat hypertension and heart failure, announces today that it has recruited […]
PARIS, May 04, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat difficult-to-treat/resistant hypertension and heart failure, announces it is strengthening its […]
PARIS, April 28, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain in order to address difficult-to-treat/resistant hypertension […]
Quantum Genomics has equipped itself with new financial means to pursue the development of firibastat and explore new therapeutic fields based on the patented technology platform built around BAPAIs Quantum Genomics is taking this opportunity to strengthen and expand its […]
Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription right A minimum of €12 million subscription commitments received from institutional investors, including €10 million from Otium Capital Raise to coincide with pharmaceutical […]
PARIS, March 31, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat resistant/hard-to-treat hypertension and heart failure, announced the publication of a […]
